Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?

  • Sumapa Chaiamnuay
  • Kenneth G. Saag


Over the past 12 years bisphosphonates have become a mainstay of treatment for postmenopausal osteoporosis. As a class, bisphosphonates significantly suppress bone turnover and increase BMD at the lumbar spine and other site through their direct inhibitory effects on osteoclasts. Alendronate and risedronate reduce the incidence of clinical vertebral and non-vertebral fractures. Etidronate and both oral and intravenous ibandronate reduce the incidence of clinical vertebral fractures, but data from primary analyses for reduction in non-vertebral fractures are currently less robust. Intravenous administration of zoledronate is under late-stage investigation for use in postmenopausal osteoporosis. Combinations of alendronate with estrogen or raloxifene provide a greater reduction in bone turnover markers and greater increases in BMD, but fracture risk reduction has not been determined. Overall, bisphosphonates are well tolerated. The most common side effects of oral bisphosphonates are upper gastrointestinal symptoms. Newer safety concerns about the use of bisphosphonates include osteonecrosis of the jaw and oversuppression of bone turnover. The optimal duration of bisphosphonate treatment has not been clearly established.


Bisphosphonates Postmenopausal osteoporosis Treatment 


  1. 1.
    Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25(1):97–106.PubMedCrossRefGoogle Scholar
  2. 2.
    Stepan JJ, Alenfeld F, Boivin G, Feyen JH, Lakatos P. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 2003;37(4):225–38.PubMedGoogle Scholar
  3. 3.
    Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(Suppl 12):2961–78.PubMedCrossRefGoogle Scholar
  4. 4.
    Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001;28(5):465–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104(10):1363–74.PubMedCrossRefGoogle Scholar
  6. 6.
    Boonen S, Haentjens P, Vandenput L, Vanderschueren D. Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes. J Intern Med 2004;255(1):1–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333(22):1437–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama 1998;280(24):2077–82.PubMedCrossRefGoogle Scholar
  9. 9.
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535–41.PubMedCrossRefGoogle Scholar
  10. 10.
    Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9(8):1137–41.PubMedCrossRefGoogle Scholar
  11. 11.
    Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85(11):4118–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999;9(5):461–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23(4):508–16.PubMedCrossRefGoogle Scholar
  14. 14.
    Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005;16(5):468–74.PubMedCrossRefGoogle Scholar
  15. 15.
    Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12(1):1–12.Google Scholar
  16. 16.
    Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21(9):1453–60.PubMedCrossRefGoogle Scholar
  17. 17.
    Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006;119(4 Suppl 1):S18–24.PubMedCrossRefGoogle Scholar
  18. 18.
    Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Jama 1999;282(14):1344–52.PubMedCrossRefGoogle Scholar
  19. 19.
    Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11(1):83–91.PubMedCrossRefGoogle Scholar
  20. 20.
    McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344(5):333–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23(4):517–23.PubMedCrossRefGoogle Scholar
  22. 22.
    Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71 2:103–11.PubMedCrossRefGoogle Scholar
  23. 23.
    Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20(1):141–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19(8):1241–9.CrossRefGoogle Scholar
  25. 25.
    Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006.Google Scholar
  26. 26.
    Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21(12):1895–903.PubMedCrossRefGoogle Scholar
  27. 27.
    Emkey MZR, Lewiecki EM, Burdeska A, Mairon N, Rowell L, Eisman JA. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study. 2005.Google Scholar
  28. 28.
    Sambrook P, Olszynski WP, Leigh C, Masanauskaite D, Bonvoisin B, Emkey R. Similar safety profile of intravenous ibandronate injection and daily oral ibandronate in postmenopausal osteoporosis: the DIVA study. Arthritis Rheum 2005;52(Suppl 9):S296.Google Scholar
  29. 29.
    Heaney RP, Saville PD. Etidronate disodium in postmenopausal osteoporosis. Clin Pharmacol Ther 1976;20(5):593–604.PubMedGoogle Scholar
  30. 30.
    Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323(2):73–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95(6):557–67.PubMedCrossRefGoogle Scholar
  32. 32.
    Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 1997;103(6):468–76.PubMedCrossRefGoogle Scholar
  33. 33.
    Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001;12(2):140–51.PubMedCrossRefGoogle Scholar
  34. 34.
  35. 35.
    van Staa TP, Leufkens H, Abenhaim L, Cooper C. Postmarketing surveillance of the safety of cyclic etidronate. Pharmacotherapy 1998;18(5):1121–8.PubMedGoogle Scholar
  36. 36.
    Ryan PJ, Blake GM, Davie M, Haddaway M, Gibson T, Fogelman I. Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. Osteoporos Int 2000;11(2):171–6.PubMedCrossRefGoogle Scholar
  37. 37.
  38. 38.
    Peretz A, Body JJ, Dumon JC, et al. Cyclical pamidronate infusions in postmenopausal osteoporosis. Maturitas 1996;25(1):69–75.PubMedCrossRefGoogle Scholar
  39. 39.
    Thiebaud D, Burckhardt P, Melchior J, et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994;4(2):76–83.PubMedCrossRefGoogle Scholar
  40. 40.
    Cauza E, Etemad M, Winkler F, et al. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. J Clin Pharm Ther 2004;29(5):431–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Chan SS, Nery LM, McElduff A, et al. Intravenous pamidronate in the treatment and prevention of osteoporosis. Intern Med J 2004;34(4):162–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Morabito N, Gaudio A, Lasco A, et al. Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. Osteoporos Int 2003;14(6):500–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346(9):653–61.PubMedCrossRefGoogle Scholar
  44. 44.
    Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999;84(9):3076–81.PubMedCrossRefGoogle Scholar
  45. 45.
    Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000;85(2):720–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001;86(5):1890–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. Jama 2003;289(19):2525–33.PubMedCrossRefGoogle Scholar
  48. 48.
    Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87(3):985–92.PubMedCrossRefGoogle Scholar
  49. 49.
    Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006;119(4 Suppl 1):S12–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Graham DY. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002;47(8):1665–78.PubMedCrossRefGoogle Scholar
  51. 51.
    Ribeiro A, DeVault KR, Wolfe JT 3rd, Stark ME. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998;47(6):525–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu TT. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Path 1999;12(12):1152–7.Google Scholar
  53. 53.
    Lichtenberger LM, Romero JJ, Gibson GW, Blank MA. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 2000;45(9):1792–801.PubMedCrossRefGoogle Scholar
  54. 54.
    Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000;95(11):3112–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Graham DY, Malaty HM, Goodgame R. Primary amino-bisphosphonates: a new class of gastrotoxic drugs—comparison of alendronate and aspirin. Am J Gastroenterol 1997;92(8):1322–5.PubMedGoogle Scholar
  56. 56.
    Graham DY, Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther 1999;13(4):515–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350(12):1189–99.PubMedCrossRefGoogle Scholar
  58. 58.
    Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002;77(3):262–70.PubMedCrossRefGoogle Scholar
  59. 59.
    Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000;119(3):631–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Thomson AB, Marshall JK, Hunt RH, et al. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 2002;29(9):1965–74.PubMedGoogle Scholar
  61. 61.
    Epstein S, Delmas PD, Emkey R, Wilson KM, Hiltbrunner V, Schimmer RC. Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. Maturitas 2006;54(1):1–10.PubMedCrossRefGoogle Scholar
  62. 62.
    Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62(5):527–34.PubMedCrossRefGoogle Scholar
  63. 63.
    Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144(10):753–61.PubMedGoogle Scholar
  64. 64.
    Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997;76(4):266–83.CrossRefGoogle Scholar
  65. 65.
    Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62(22):6538–44.PubMedGoogle Scholar
  66. 66.
    Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8(5):1080–4.PubMedGoogle Scholar
  67. 67.
    Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000;15(4):613–20.PubMedCrossRefGoogle Scholar
  68. 68.
    Allen M, Iwata K, Phipps, R, Burr, DB. Risedronate and Alendronate similarly suppress remodelling and increase microdamage in beagles after 1 year of treatment at clinical doses. JBMR 2005.Google Scholar
  69. 69.
    Currey JD. Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci 1984;304(1121):509–18.PubMedCrossRefGoogle Scholar
  70. 70.
    Ott SM. Fractures after long-term alendronate therapy. J Clin Endocrinol Metab 2001;86(4):1835–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004;19(8):1259–69.PubMedCrossRefGoogle Scholar
  72. 72.
    Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75(6):462–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Recker R. Alendronate effects on histomorphometric parameters: is there evidence for over-suppression of turnover? JMBR 2005Google Scholar
  74. 74.
    Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90(3):1294–301.PubMedCrossRefGoogle Scholar
  75. 75.
    Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90(3):1897–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Emkey R, Zaidi M, Lewiecki EM, Burdeska A, Mairon N, Rowell L, et al. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study. 2005.Google Scholar
  77. 77.
  78. 78.
  79. 79.
  80. 80.
    Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 2005;27(4):361–76.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2006

Authors and Affiliations

  1. 1.Division of Clinical Immunology and RheumatologyUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.FOT 820BirminghamUSA

Personalised recommendations